common/消炎（药

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to the treatment of the common cold and, more particularly, to a method and kit for cold treatment which employs both antiviral and antimediator agents. 2. Description of the Prior Art The "common cold" is

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to the treatment of the common cold and, more particularly, to a method and kit for cold treatment which employs both antiviral and antimediator agents. 2. Description of the Prior Art The "common cold" is

DESCRIPTION BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention generally relates to the treatment of the common cold and, more particularly, to a method and kit for cold treatment which employs both antiviral and antimediator agents. 2. Description of the Prior Art The

FIELD OF THE INVENTION The present invention relates to novel prodrugs of NSAIDs comprising an immobility promoting unit covalently linked, in the form of an ester bond, to an active pharmaceutical ingredient, i.a. common NSAIDs. The novel compounds are soluble at acidic pH but precipitate at

BACKGROUND OF THE INVENTION The accumulation bacteria in the oral cavity, such as on the teeth or tongue has been identified as a contributor or cause of various inflammatory conditions, including gingivitis, periodontitis and other gum diseases. Treatment of the oral cavity with antibiotics to

FIELD OF THE INVENTION The present invention relates to novel sulfonamide derivatives, to pharmaceutical compositions comprising the same, and to uses thereof. Compounds of the invention have a common wide range of beneficial therapeutic indications. In particular, compounds of the invention are

CROSS REFERENCE TO RELATED APPLICATION This application is a continuation-in-part of International Patent Application No. PCT/US2010/020712, filed Jan. 12, 2010 and claims the benefit from Italian Patent Application No. MI2009A000019, filed Jan. 12, 2009. The content of this application is

The present invention refers to complexes between bilobalide, a sesquiterpene extracted from the leaves of Gingko biloba, and natural or synthetic phospholipids, to the preparation thereof and to the therapeutical use thereof. The complexes prepared according to the procedure described in the

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates generally to the fields of cancer biology and biochemistry. More particularly, the present invention is directed to a method of cancer chemotherapy in mammals. 2. Description of Related Art Mutational activation of

TECHNICAL FIELD The present invention relates to antibiotics, anti-inflammatory agents, anti-hyperlipidemia agents, anti-diabetes agents and anticancer agents, manufactured using an old platycodon extract, based on various pharmacological effects of 20-year (or older) old platycodon produced in

BACKGROUND OF THE INVENTION 1. Field of the Invention The invention relates to the use of oligo- and/or polysaccharides containing the sugar building block N-acylglucosamine and/or N-acylgalactosamine for the preparation of hemocompatible surfaces, methods for the hemocompatible coating of surfaces

FIELD OF THE INVENTION The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of

CROSS REFERENCE TO RELATED PATENT APPLICATION The present application is the US national stage of PCT/CN2009/075994 filed on Dec. 24, 2009, which claims the priority of the Chinese patent application No. 200910026697.9 filed on May 11, 2009, which application is incorporated herein by

BACKGROUND OF THE INVENTION Transforming Growth Factor .beta. (TGF-.beta.) is a potent growth regulatory protein and a key molecule implicated in various fibrotic (scarring) disorders. Most of the cells secrete TGF-.beta.1 in a predominantly inactive high molecular weight form, latent TGF-.beta.

BACKGROUND OF THE INVENTION The technical field of this invention concerns the encapsulation of living cells for the production of biologically active factors. There is considerable interest at present in the biologically active products of living cells, including, for example, neurotransmitters,